Allogeneic stem cell transplantation is still a highly curative therapy in adults with philadelphia chromosome–positive acute lymphoblastic leukaemia
Annals of Hematology(2024)
摘要
The application of tyrosine kinase inhibitors (TKIs) and novel immunotherapies has improved outcomes in patients with Ph + acute lymphoblastic leukaemia (ALL), and the issue of whether there is still a need for stem cell transplantation has become controversial. We performed a retrospective study to explore whether stem cell transplantation still held a place in patients with Ph + ALL if only imatinib and 2nd generation TKIs are available and affordable. A total of 292 patients were included. The median age was 38 years [range 14–64, IQR 28–48]. Patients receiving transplants (n = 216) had better rates of 4-year disease-free survival (DFS, 68
更多查看译文
关键词
Philadelphia chromosome–positive acute lymphoblastic leukaemia,Tyrosine kinase inhibitors,Molecular response,Allogeneic stem cell transplantation
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要